Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Ibrahim

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Interpersonal Violence|June 2, 2021
Health Correlates of Intimate Partner Violence and Help-seeking Among Unauthorized Immigrant WomenSara Shuman, Amanda M Pollitt, Matthew O'Brien, et al.
Molecular Genetics and Metabolism Reports|July 14, 2016
Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher RegistryJennifer Ibrahim, Lisa H Underhill, John S Taylor, et al.
Molecular Genetics and Metabolism Reports|January 30, 2020
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1Lucie Vu, Gerald F Cox, Jennifer Ibrahim, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 6, 2024
Rheumatology High Blood Pressure Protocol Reduces Disparities, But Delays Remain for External Primary CareSancia Ferguson, Bret M Hanlon, Edmond Ramly, et al.
Public Health Reports (Washington, D.C. : 1974)|January 27, 2017
Better Health Faster: The 5 Essential Public Health Law ServicesScott Burris, Marice Ashe, Doug Blanke, et al.
Molecular Genetics and Metabolism|February 8, 2020
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agentsNathan Thibault, Jennifer Ibrahim, M Judith Peterschmitt, et al.
Blood Cells, Molecules & Diseases|January 28, 2017
A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and durationM Judith Peterschmitt, Gerald F Cox, Jennifer Ibrahim, et al.
Social Work in Public Health|July 14, 2022
"Unprecedented Times:" Experiences of Social Work and Public Health Professionals during Times of Public CrisesLiliana Ventura, Christina M Chiarelli-Helminiak, Anne S Frankel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 15, 2013
The recurrent distal 22q11.2 microdeletions are often de novo and do not represent a single clinical entity: a proposed categorization systemFady M Mikhail, Rachel D Burnside, Brooke Rush, et al.
Human Mutation|July 17, 2015
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype CorrelationKitiwan Rojnueangnit, Jing Xie, Alicia Gomes, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Interpersonal Violence|June 2, 2021
Health Correlates of Intimate Partner Violence and Help-seeking Among Unauthorized Immigrant WomenSara Shuman, Amanda M Pollitt, Matthew O'Brien, et al.
Molecular Genetics and Metabolism Reports|July 14, 2016
Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher RegistryJennifer Ibrahim, Lisa H Underhill, John S Taylor, et al.
Molecular Genetics and Metabolism Reports|January 30, 2020
Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1Lucie Vu, Gerald F Cox, Jennifer Ibrahim, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|March 6, 2024
Rheumatology High Blood Pressure Protocol Reduces Disparities, But Delays Remain for External Primary CareSancia Ferguson, Bret M Hanlon, Edmond Ramly, et al.
Public Health Reports (Washington, D.C. : 1974)|January 27, 2017
Better Health Faster: The 5 Essential Public Health Law ServicesScott Burris, Marice Ashe, Doug Blanke, et al.
Molecular Genetics and Metabolism|February 8, 2020
Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agentsNathan Thibault, Jennifer Ibrahim, M Judith Peterschmitt, et al.
Blood Cells, Molecules & Diseases|January 28, 2017
A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and durationM Judith Peterschmitt, Gerald F Cox, Jennifer Ibrahim, et al.
Social Work in Public Health|July 14, 2022
"Unprecedented Times:" Experiences of Social Work and Public Health Professionals during Times of Public CrisesLiliana Ventura, Christina M Chiarelli-Helminiak, Anne S Frankel, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 15, 2013
The recurrent distal 22q11.2 microdeletions are often de novo and do not represent a single clinical entity: a proposed categorization systemFady M Mikhail, Rachel D Burnside, Brooke Rush, et al.
Human Mutation|July 17, 2015
High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype CorrelationKitiwan Rojnueangnit, Jing Xie, Alicia Gomes, et al.
Pageof 3